The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
Stock and Other Ownership Interests - Exelixis; Merck; Roche; Teva
Patents, Royalties, Other Intellectual Property - Exelixis; Exelixis (Inst)
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
 
Jose Baselga
Leadership - Infinity Pharmaceuticals; Varian Medical Systems
Stock and Other Ownership Interests - GRAIL; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma; Varian Medical Systems
Consulting or Advisory Role - Eli Lilly, Novartis; GRAIL
 
Javier Cortés
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Roche
 
Michelino DeLaurentiis
Honoraria - Novartis; Pfizer; Roche
Consulting or Advisory Role - Novartis; Pfizer; Roche
 
Susan Dent
Consulting or Advisory Role - Roche
Research Funding - Roche
 
Véronique Diéras
Consulting or Advisory Role - Abbvie; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Nadia Harbeck
Honoraria - Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Celgene; Hexal; Novartis; Pfizer; Roche/Genentech; Sandoz
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Jerry Y. Hsu
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Huan Jin
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Frauke Schimmoller
No Relationships to Disclose
 
Timothy R. Wilson
Employment - Genentech
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Genentech
 
Young-Hyuck Im
No Relationships to Disclose
 
William Jacot
No Relationships to Disclose
 
Ian E Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Consulting or Advisory Role - Amgen; Genentech
Research Funding - Genentech
 
Sunil Verma
Leadership - Gynesonics
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Lilly; Novartis; Roche/Genentech